- Home
- ALV vs CORT Comparison
ALV vs CORT Comparison
Compare ALV & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALV | CORT |
|---|---|---|
| Founded | 1953 | 1998 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 8.6B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | ALV | CORT |
|---|---|---|
| Price | $118.46 | $35.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $133.45 | $130.20 |
| AVG Volume (30 Days) | 470.8K | ★ 2.1M |
| Earning Date | 01-30-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | ★ 25.57 | N/A |
| EPS | ★ 9.69 | 0.87 |
| Revenue | ★ $10,614,000,000.00 | $741,172,000.00 |
| Revenue This Year | $4.71 | $23.96 |
| Revenue Next Year | $4.08 | $43.40 |
| P/E Ratio | ★ $12.25 | $39.84 |
| Revenue Growth | 0.85 | ★ 17.92 |
| 52 Week Low | $75.49 | $32.99 |
| 52 Week High | $129.54 | $117.33 |
Technical Indicators
Market Signals| Indicator | ALV | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 45.82 | 14.56 |
| Support Level | $119.38 | $80.38 |
| Resistance Level | $121.53 | $85.34 |
| Average True Range (ATR) | 1.65 | 4.01 |
| MACD | -0.09 | -3.98 |
| Stochastic Oscillator | 9.58 | 4.40 |
Price Performance
Historical ComparisonAbout ALV Autoliv Inc.
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.